NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCTs021240010

Registered date:13/06/2024

Exploratory randomized controlled trial of cystine-theanine for cancer cachexia

Basic Information

Recruitment status Pending
Health condition(s) or Problem(s) studiedAdvanced lung cancer
Date of first enrollment13/06/2024
Target sample size50
Countries of recruitment
Study typeInterventional
Intervention(s)cystine and theanine

Outcome(s)

Primary OutcomeChange of QOL (FAACT-SEA) from baseline to Day 28
Secondary OutcomeQOL ( FAACT (A/CS) ) on Day 28, IL-6, Adverse Events

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximumNot applicable
GenderBoth
Include criteria1) any gender over 20 years old 2) Diagnosed as lung cancer 3) Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 - 2 4) With 5 percent weight loss within 6 months and appetite loss, and 2 factors among 3 factors below (i) fatigue (ii) systemic muscle weakness (iii) CRP>0.5 mg/dL or Hb<12 g/dL or serum albumin<3.2 g/dL 5) Adequate organ function within 14 days before registration as below (i) neutrophil count > 1500 / microlitre (ii) platelet count > 75000 / microlitre (iii) Hemoglobin > 8.0 g / dL (iv) Total bilirubin < 2.0 mg / dL (v) AST < 100 U / L (vi) ALT < 100 U / L (vii) Serum creatinine < 1.5 mg / dL 6) Written informed consent
Exclude criteria1) Take in a healthy product of amino acids (including protein) or those derived from herb including Saint Jones Wirt except the multivitamin nutritional supplement 2) Planned the chemotherapy with the moderate emetic above-mentioned anticancer agent (ex. Platinum agents, irinotecan, amurubicin, celitinib, crizotinib) during the examination period (one months) 3) Treatment with Anamorelin is planned within the period of this study 4) Impossible oral intake 5) With malabsorption syndrome or active gastrointestinal bleeding or past history of the gastric resection 6) Being pregnant or nursing baby 7) With immunodeficiency or phenylketonuria 8) Withe cognitive impairment such as dementia or delirium 9) With neurologic mental obstacle to affect the data collection 10) Impossible communication because of aphasia, loss of voice, or dysarthria 11) Judged as inappropriate for registration by attending physician

Related Information

Contact

Public contact
Name Akira Inoue
Address 1-1, Seiryocho, Aobaku, Sendai, Miyagi Miyagi Japan 980-8574
Telephone +81-22-717-7366
E-mail akira.inoue.b2@tohoku.ac.jp
Affiliation Tohoku University Hospital
Scientific contact
Name Akira Inoue
Address 1-1, Seiryocho, Aobaku, Sendai, Miyagi Miyagi Japan 980-8574
Telephone +81-22-717-7366
E-mail akira.inoue.b2@tohoku.ac.jp
Affiliation Tohoku University Hospital